Abstract:Current drug therapy fails to reduce lung destruction of chronic obstructive pulmonary disease (COPD). AMP-activated protein kinase (AMPK) has emerged as an important integrator of signals that control energy balance and lipid metabolism. However, there are no studies regarding the role of AMPK in reducing inflammatory responses and cellular senescence during the development of emphysema. Therefore, we hypothesize that AMPK reduces inflammatroy responses, senescence, and lung injury. To test this hypothesis, human bronchial epithelial cells (BEAS-2B) and small airway epithelial cells (SAECs) were treated with cigarette smoke extract (CSE) in the presence of a specific AMPK activator (AICAR, 1 mM) and inhibitor (Compound C, 5 μM). Elastase injection was performed to induce mouse emphysema, and these mice were treated with a specific AMPK activator metformin as well as Compound C. AICAR reduced, whereas Compound C increased CSE-induced increase in IL-8 and IL-6 release and expression of genes involved in cellular senescence. Knockdown of AMPKα1/α2 increased expression of pro-senescent genes (e.g., p16, p21, and p66shc) in BEAS-2B cells. Prophylactic administration of an AMPK activator metformin (50 and 250 mg/kg) reduced while Compound C (4 and 20 mg/kg) aggravated elastase-induced airspace enlargement, inflammatory responses and cellular senescence in mice. This is in agreement with therapeutic effect of metformin (50 mg/kg) on airspace enlargement. Furthermore, metformin prophylactically protected against but Compound C further reduced mitochondrial proteins SOD2 and SIRT3 in emphysematous lungs. In conclusion, AMPK reduces abnormal inflammatory responses and cellular senescence, which implicates as a potential therapeutic target for COPD/emphysema.

Preclinical evidence using synthetic compounds and natural products indicates that AMPK represents a potential pharmacological target for the therapy of pulmonary diseases

Molecular pathogenesis in chronic obstructive pulmonary disease and therapeutic potential by targeting AMP-activated protein kinase: AMPK in chronic obstructive pulmonary disease

Role of AMPK in pulmonary diseases

Molecular Pathogenesis in Chronic Obstructive Pulmonary Disease and Therapeutic Potential by Targeting AMP‐activated Protein Kinase

Adenosine monophosphate, one metabolite from lower respiratory tract, promotes the progression of pulmonary arterial hypertension through the PI3K/AKT signaling pathway in pediatric with congenital heart disease

AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling

Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies

The role and mechanism of AMPK in pulmonary hypertension

AMPK and Diseases: State of the Art Regulation by AMPK-Targeting Molecules

Activation of AMPK Α2 Inhibits Airway Smooth Muscle Cells Proliferation

Knockdown of AMPKα2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27Kip1 Signaling Pathway

Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

AMP-activated protein kinase: the current landscape for drug development

AMP-activated protein kinase reduces inflammatory responses and cellular senescence in pulmonary emphysema

Knockdown of AMPKα2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway.

Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer

Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease: Evidence from Studies of Natural Products

Crosstalk of 5′-Monophosphate-Activated Protein Kinase (AMPK) with Extracellular and Intracellular Signaling Pathways in the Regulation of Nutrient Metabolism and Cell Survival in the Liver

AMPK Alchemy: Therapeutic Potentials in Allergy, Aging, and Cancer

AMPK as a Therapeutic Target for Treating Metabolic Diseases